References
- Nijland M, Jansen A, Doorduijn JK, et al. Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma. Leuk Lymphoma. 2017;58:2074–2079.
- El-Galaly TC, Cheah CY, Bendtsen MD, et al. An international collaborative study of outcome and prognostic factors in patients with secondary CNS involvement by diffuse large B-cell lymphoma. Blood. 2016;128:1874–1874.
- van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91:1178–1184.
- Harder H, Holtel H, Bromberg JE, et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology. 2004;62:544–547.
- Chen Y-B, Batchelor T, Li S, et al. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015;121:226–233.
- Ferreri AJM, Donadoni G, Cabras MG, et al. High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II Trial. J Clin Oncol. 2015;33:3903–3910.
- Korfel A, Elter T, Thiel E, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98:364–370.
- Cheah CY, Joske D, Cull G, et al. High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma. Br J Haematol. 2016. DOI:10.1111/bjh.14187
- Chihara D, Fowler NH, Oki Y, et al. Dose-adjusted EPOCH-R and mid-cycle high dose methotrexate for patients with systemic lymphoma and secondary CNS involvement. Br J Haematol. 2016. DOI:10.1111/bjh.14267
- Ferreri AJM, Cwynarski K, Pulczynski EJ, et al. Effects on survival and neurocognitive functions of whole-brain radiotherapy (WBRT) and autologous stem cell transplantation (ASCT) as consolidation options after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary CNS Lymphoma (PCNSL): results of the second randomization of the IELSG32 Trial. Blood. 2016;128:511–511.
- Houillier C, Taillandier L, Lamy T, et al. Whole brain radiotherapy (WBRT) versus intensive chemotherapy with haematopoietic stem cell rescue (IC + HCR) for primary central nervous system lymphoma (PCNSL) in young patients: an intergroup anocef-goelams randomized phase II trial (PRECIS). Blood. 2016;128:782–782.